Literature DB >> 18281829

Clinical significance of pacemaker-detected atrial high-rate episodes.

Anisha Mandava1, Suneet Mittal.   

Abstract

PURPOSE OF REVIEW: Pacemakers currently being implanted offer several advanced diagnostic features. Among these is the ability to store counters and intracardiac electrograms of individual atrial high-rate episodes, which are a surrogate of atrial fibrillation. As the majority of these episodes are brief and asymptomatic, their clinical significance remains to be determined. The purpose of this review is to provide a better understanding of the clinical significance of pacemaker-detected atrial high-rate episodes. RECENT
FINDINGS: Follow-up after dual-chamber pacemaker implantation demonstrates that nearly 30% of patients without a known history of atrial fibrillation develop an atrial high-rate episode lasting 5 min or more. Patients experiencing such an episode are at a twofold increased risk of stroke and death. An important risk factor for developing an atrial high-rate episode is a high burden of right ventricular pacing, suggesting that ventricular pacing should be minimized whenever possible.
SUMMARY: Atrial high-rate episodes are frequently observed in patients after dual-chamber pacemaker implantation and can be associated with adverse outcomes. Ongoing studies seek to determine whether the overall burden of these episodes correlates with the risk of thromboembolism, especially in patients without a history of atrial fibrillation, which would help guide decision-making regarding the initiation of anticoagulation.

Entities:  

Mesh:

Year:  2008        PMID: 18281829     DOI: 10.1097/HCO.0b013e3282f20a88

Source DB:  PubMed          Journal:  Curr Opin Cardiol        ISSN: 0268-4705            Impact factor:   2.161


  1 in total

1.  Stroke incidence and anticoagulation treatment in patients with pacemaker-detected silent atrial fibrillation.

Authors:  Emma Sandgren; Cecilia Rorsman; Nils Edvardsson; Johan Engdahl
Journal:  PLoS One       Date:  2018-09-13       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.